Clinical Trials Browser

Phase 2 × NIH × glembatumumab vedotin × Clear all

NCT02487979 2022-01-18

Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma

Phase 2 Completed

22 enrolled 15 charts

Osteosarcoma

NCT02363283 2020-08-21

Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma

Phase 2 Completed

37 enrolled 12 charts

Uveal Melanoma